BioSpace News Archive

LumiraDx a next-generation point of care diagnostics company announced that the intended use for its Food and Drug Administration Emergency Use Authorization authorized SARS-CoV-2 Antigen Test has been expanded to include screening of asymptomatic individuals.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights.

Acadia Pharmaceuticals Inc. announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date to February 28, 2022 for the ciltacabtagene autoleucel Biologics License Application.

Bruker Corporation announced financial results for its third quarter and for the nine months ended September 30, 2021.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent corporate updates on Monday, November 8.

Inhibrx, Inc., a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.

Telix Pharmaceuticals Limited announces that the Australian Therapeutic Goods Administration has approved Illuccix®, the Company’s lead prostate cancer imaging product.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on October 29, 2021 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase 8,400 shares of its common stock to a new employee under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that the U.S. Food and Drug Administration has accepted the New Drug Application for Maxigesic® IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain.